Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Don Walster who wrote (1002)	7/14/1998 8:51:00 PM
From: NeuroInvestment	Read Replies (4) of 1491

If you are suggesting that the 3-4 year timeframe has turned off investors, I would have to disagree. The market has hardly been that rational. Investors have not even looked Pharmos' way to begin with, and have not taken the time to figure out the prospects for HU-211. Companies have skyrocketed on the basis of angiogenesis compounds that are still in rodent studies, that have never even been in humans...thus their timeframe is even more extended. Besides, PARS has something most little biotech companies with 3-4 year timeframes do not have...a major revenue stream now building. NeuroInvestment (www.neuroinv.com)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next